15 May 2024 - NICE has published final evidence-based recommendations on the use of tisagenlecleucel (Kymriah) for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia.

Tisagenlecleucel is recommended as an option for the treatment of patients 25 years and under with B‑cell acute lymphoblastic leukaemia that has relapsed after a transplant, or relapsed for a second or later time, or refractory.

Read NICE technology appraisal guidance